Study guide

3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing

ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring

1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal

2 Chapter 2: Assessment Foundations & Lifespan Considerations

2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)

3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation

3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles

4 Chapter 4: Cardiovascular Disorders

4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

5 Chapter 5: Respiratory Disorders

5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules

6 Chapter 6: HEENT & Allergic/Immunologic Disorders

6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency

7 Chapter 7: Endocrine & Metabolic Disorders

7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism

8 Chapter 8: Gastrointestinal & Hepatic Disorders

8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening

9 Chapter 9: Renal, Urological & Men's Health

9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

10 Chapter 10: Musculoskeletal & Rheumatologic Disorders

10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes

11 Chapter 11: Neurological & Psychiatric Disorders

11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care

12 Chapter 12: Dermatologic, Hematologic & Infectious Disease

12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies

13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care

13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions

14 Chapter 14: Gynecologic & Women's Health

14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)

15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination

15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment

16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement

16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics

3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing

Key Takeaways Explain This Topic AI

Diagnostic imaging selection requires balancing diagnostic yield against radiation exposure and contrast risks: Non-contrast head CT is mandatory first-line for acute stroke/trauma to rule out hemorrhage; CT Pulmonary Angiography (CTPA) is gold standard for pulmonary embolism; and Point-of-Care Ultrasound (POCUS) provides rapid, radiation-free evaluation of gallbladder, deep veins, and cardiac function.

Contrast-induced nephropathy prevention requires identifying high-risk patients (eGFR <30 mL/min/1.73m²) and administering IV isotonic saline hydration; oral metformin must be held at the time of iodinated contrast administration in patients with eGFR <60 or hepatic dysfunction and held for 48 hours until stable renal function is documented.

Systematic 12-lead ECG analysis follows an invariant sequence: Rate, Rhythm, Axis, Intervals (PR, QRS, QTc), Chamber Enlargement, and Ischemia/Infarction localization across coronary anatomical distributions.

Acute STEMI patterns correlate with coronary anatomy: Inferior (II, III, aVF = RCA; requires right-sided V4R lead check and avoidance of nitrates if RV involved); Anterior/Septal (V1-V4 = LAD); Lateral (I, aVL, V5, V6 = LCx/LAD). Wellens syndrome (biphasic/deeply inverted T waves in V2-V3) indicates critical proximal LAD stenosis.

Pulmonary Function Testing (PFT) follows a 5-step sequence: Step 1 FEV1/FVC <0.70 confirms airflow obstruction; Step 2 assess FEV1 severity (GOLD 1-4); Step 3 test bronchodilator reversibility (ΔFEV1/FVC >12% and >200 mL); Step 4 if FEV1/FVC normal and FVC low, verify restriction via plethysmography (TLC <80%); Step 5 evaluate DLCO to distinguish emphysema/ILD (low DLCO) from asthma/chest wall restriction (normal DLCO).

Last updated: August 2026

Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing

Advanced clinical interpretation requires the AGPCNP to integrate multimodal structural, electrical, and physiological diagnostics. Mastering the indications, contraindications, systematic interpretation frameworks, and critical clinical pearls of diagnostic imaging, 12-lead electrocardiography (ECG), and pulmonary function testing (PFT) is paramount for competent adult-gerontology practice and board examination excellence.

1. Systematic Diagnostic Imaging Selection & Contrast Safety +-----------------------------------------------------------------------------+

  • | DIAGNOSTIC IMAGING SELECTION MATRIX |
  • | |
  • | MODALITY PRIMARY INDICATIONS SAFETY / CONTRAINDICATIONS|
  • | +--------------------+ +--------------------------+ +--------------------+|
  • | | Non-Contrast CT | | Acute stroke, intracranial| | Avoid in pregnancy; ||
  • | | Head / Spine | | hemorrhage, head trauma, | | high cumulative ||
  • | | | | renal colic (calculi) | | radiation dose. ||
  • | +--------------------+ +--------------------------+ +--------------------+|
  • | | IV Contrast- | | Pulmonary embolism (CTPA)| | Check eGFR (<30 ml);||
  • | | Enhanced CT | | Acute abdomen, dissection| | Hold metformin 48h;||
  • | | (Iodinated) | | Bowel perforation/abscess| | Premedicate allergy.||
  • | +--------------------+ +--------------------------+ +--------------------+|
  • | | MRI / MRA | | Ischemic stroke (DWI), | | Pacemakers/ICDs, ||
  • | | (Gadolinium) | | Spinal cord compression, | | metallic implants; ||
  • | | | | soft tissue tumors, MS | | GFR <30 (NSF risk). ||
  • | +--------------------+ +--------------------------+ +--------------------+|
  • | | Ultrasound / | | Cholecystitis, DVT duplex| | Operator dependent; ||
  • | | POCUS / Echo | | AAA screen, pelvic mass | | safe in pregnancy; ||
  • | | | | Heart failure / EF% | | zero radiation. ||
  • | +--------------------+ +--------------------------+ +--------------------+|
  • +-----------------------------------------------------------------------------+
  • Systematic Chest Radiography (CXR): The ABCDEF Approach

When analyzing a standard Posteroanterior (PA) and Lateral CXR, execute an invariant reading algorithm:

A — Airway: Trachea midline vs. shifted (shifted toward atelectasis/pneumonectomy; shifted away from tension pneumothorax or large pleural effusion); carina angle (<90°); visible mainstem bronchi.

B — Bones & Soft Tissues: Clavicles, ribs (posterior rib fractures, lytic lesions in multiple myeloma), cervical spine, subcutaneous emphysema (crepitus/gas streaks in neck/chest wall from esophageal or bronchial rupture).

C — Cardiac Silhouette & Mediastinum: Cardiothoracic ratio on PA view ( > 0.50 >0.50 > 0.50 indicates cardiomegaly); aortic arch contour; mediastinal width ( > 8 >8 > 8 cm at superior mediastinum suggests thoracic aortic dissection or mediastinitis).

D — Diaphragm & Costophrenic Angles: Sharp, acute costophrenic angles (blunting requires ≥ 175 \ge 175 ≥ 175 mL fluid on PA view, ≥ 50 \ge 50 ≥ 50 mL on lateral view); hemi-diaphragm contour (right hemi-diaphragm sits 1 − 2 1-2 1 − 2 cm higher than left due to liver); free air under diaphragm (pneumoperitoneum indicating hollow viscus perforation).

E — Effusions & Extrathoracic Structures: Meniscus sign (pleural effusion); gastric air bubble location; surgical clips, pacemaker leads, PICC line tip placement (caval-atrial junction).

F — Fields of the Lungs: Inspect symmetry across upper, middle, and lower zones. Silhouette sign (loss of normal anatomical margin):

Loss of right heart border = Right Middle Lobe consolidation.

Loss of left heart border = Lingular consolidation.

Loss of hemi-diaphragm = Lower Lobe consolidation.

Air Bronchograms (tubular lucencies of air-filled bronchi surrounded by fluid-filled alveoli) confirm alveolar consolidation (pneumonia or non-cardiogenic pulmonary edema).

Kerley B Lines (horizontal 1–2 cm peripheral lines at lung bases touching pleura) indicate interstitial pulmonary edema and elevated pulmonary capillary wedge pressure.

Iodinated Contrast Protocols & Metformin Stewardship

Contrast-Induced Nephropathy (CIN) Prevention: CIN is defined as an absolute increase in serum creatinine of ≥ 0.5 \ge 0.5 ≥ 0.5 mg/dL or a relative increase of ≥ 25 % \ge 25\% ≥ 25% from baseline within 48–72 hours following iodinated contrast administration.

High-Risk Threshold: Baseline eGFR < 30 <30 < 30 mL/min/1.73m 2 ^2 2 , active diabetic nephropathy, congestive heart failure, dehydration.

Evidence-Based Prevention: Intravenous volume expansion with isotonic crystalloids (0.9% Normal Saline at 1.0–1.5 mL/kg/hr for 3–12 hours pre-procedure and 6–12 hours post-procedure). Routine prophylactic N-acetylcysteine or sodium bicarbonate is no longer superior to isotonic saline alone.

Metformin Protocol with Iodinated Contrast:

Metformin does not cause renal failure, but if contrast induces acute renal failure, metformin accumulates, precipitating fatal Metformin-Associated Lactic Acidosis (MALA) .

Action Rule: In patients with baseline eGFR < 60 <60 < 60 mL/min/1.73m 2 ^2 2 , hepatic dysfunction, or undergoing arterial catheterization, withhold Metformin at the time of contrast administration , hold for 48 hours post-procedure , and resume only after documenting stable renal function via repeat serum creatinine/eGFR.

Contrast Allergy Premedication Regimen (Elective):

Oral Prednisone 50 mg at 13 hours, 7 hours, and 1 hour prior to contrast injection, plus Diphenhydramine 50 mg IV/oral 1 hour prior.

2. Systematic 12-Lead Electrocardiogram (ECG) Interpretation +-----------------------------------------------------------------------------+

  • | INVARIANT 6-STEP ECG ALGORITHM |
  • | |
  • | 1. RATE ---> 300-150-100-75-60-50 method or (QRS in 6 sec) x 10 |
  • | 2. RHYTHM ---> Sinus P waves (upright I, II, aVF; inverted aVR)? |
  • | 3. AXIS ---> Lead I and aVF Quadrant Method |
  • | 4. INTERVALS ---> PR (120-200ms), QRS (<120ms), QTc (<440ms M, <460ms F)|
  • | 5. HYPERTROPHY ---> LVH (Sokolow-Lyon: S in V1 + R in V5/V6 >= 35 mm) |
  • | 6. ISCHEMIA ---> ST Elevation / Depression, T wave inversion, Q waves |
  • +-----------------------------------------------------------------------------+

Mean QRS Electrical Axis Determination +-----------------------------------------------------------------------------+

  • | QUADRANT AXIS DETERMINATION |
  • | |
  • | LEAD I NET QRS LEAD aVF NET QRS ELECTRICAL AXIS CLASSIFICATION|
  • | + (Positive) + (Positive) NORMAL AXIS (-30° to +90°) |
  • | + (Positive) - (Negative) Check Lead II: |
  • | - If II is +, Normal Axis |
  • | - If II is -, LEFT AXIS (-30° to -90°)|
  • | - (Negative) + (Positive) RIGHT AXIS DEVIATION (+90° to +180°)|
  • | - (Negative) - (Negative) EXTREME AXIS / "NORTHWEST" |
  • +-----------------------------------------------------------------------------+
  • Coronary Artery Territory & Ischemia Localization

Anatomical Cardiac Region Involved ECG Leads Culprit Coronary Artery Reciprocal ST Depression Leads Critical Clinical Pearls

Inferior Wall II, III, aVF Right Coronary Artery (RCA) (~85%) or Left Circumflex (LCx) (~15%) Leads I, aVL • Check right-sided precordial leads ( V3R, V4R ) for Right Ventricular Infarction.; • Avoid Nitrates, Morphine, and Diuretics in RV infarction (patient is preload-dependent; nitrates trigger catastrophic hypotension). Treat hypotension with IV saline boluses.; • High risk of sinus bradycardia and high-grade AV block (RCA supplies SA and AV nodes).

Septal Wall V1, V2 Left Anterior Descending (LAD) (Septal perforators) None Associated with Bundle Branch Blocks and intraventricular conduction delays.

Anterior Wall V3, V4 Left Anterior Descending (LAD) ("Widow-maker") Inferior leads (II, III, aVF) High risk of cardiogenic shock, acute pulmonary edema, ventricular free wall rupture, and ventricular tachycardia.

Lateral Wall I, aVL, V5, V6 Left Circumflex (LCx) or Diagonal branch of LAD Inferior leads (II, III, aVF) High lateral (I, aVL) vs. Low lateral (V5, V6).

Posterior Wall V7, V8, V9 (ST elevation ≥ 0.5 \ge 0.5 ≥ 0.5 mm) RCA or LCx (Posterior descending) V1, V2, V3 ( Horizontal ST depression, tall broad R waves [R/S ratio >1], upright prominent T waves ) True posterior STEMI is frequently missed because standard 12-lead shows "mirror image" ST depressions in V1-V3. Obtain posterior leads (V7-V9). +-----------------------------------------------------------------------------+

  • | HIGH-RISK ECG PATTERNS & STEMI EQUIVALENTS |
  • | |
  • | WELLENS SYNDROME TYPE A ---> Biphasic T waves in V2-V3 |
  • | WELLENS SYNDROME TYPE B ---> Deeply inverted symmetric T waves in V2-V3 |
  • | Significance: Critical proximal LAD stenosis|
  • | Action: Urgent cath; STRESS TEST CONTRAINDICATED!|
  • | |
  • | de WINTER T WAVES ---> 1-3 mm upsloping ST depression at J-point |
  • | followed by tall, prominent, symmetric T |
  • | waves in V1-V6. (Acute LAD occlusion). |
  • | |
  • | ACUTE PERICARDITIS ---> Diffuse, concave-upward ST elevation across|
  • | all leads (I, II, aVF, V2-V6) + PR DEPRESSION.|
  • | Lead aVR shows PR ELEVATION and ST DEPRESSION.|
  • +-----------------------------------------------------------------------------+

Atrioventricular (AV) Blocks & Bundle Branch Blocks +-----------------------------------------------------------------------------+

  • | ATRIOVENTRICULAR (AV) BLOCK TAXONOMY |
  • | |
  • | FIRST-DEGREE AV BLOCK ---> PR interval > 200 ms (>5 small boxes); |
  • | every P wave is followed by a QRS (1:1). |
  • | |
  • | SECOND-DEGREE MOBITZ I ---> Progressive PR prolongation until a QRS is |
  • | (WENCKEBACH) dropped ("Longer, longer, longer, drop!"). |
  • | Pathology: AV Node. Usually benign/stable. |
  • | |
  • | SECOND-DEGREE MOBITZ II ---> Constant, fixed PR interval with intermittent|
  • | dropped QRS complexes without warning. |
  • | Pathology: His-Purkinje. HIGH RISK OF CHB! |
  • | Action: Pacemaker required. |
  • | |
  • | THIRD-DEGREE (COMPLETE) ---> Complete AV dissociation; P waves and QRS |
  • | HEART BLOCK beat independently (PP regular, RR regular).|
  • | Action: Emergent transcutaneous/transvenous |
  • | pacing; permanent pacemaker implantation. |
  • +-----------------------------------------------------------------------------+

Left Bundle Branch Block (LBBB): QRS duration ≥ 120 \ge 120 ≥ 120 ms (3 small boxes); broad, notched, or slurred R waves in lateral leads (I, aVL, V5, V6); deep, broad S waves in V1-V2; absence of septal Q waves in lateral leads.

Sgarbossa Criteria for MI in pre-existing LBBB: Concordant ST elevation ≥ 1 \ge 1 ≥ 1 mm in leads with positive QRS (5 pts); Concordant ST depression ≥ 1 \ge 1 ≥ 1 mm in leads V1-V3 (3 pts); Proportionally excessive discordant ST elevation ≥ 25 % \ge 25\% ≥ 25% of the depth of the preceding S wave (2 pts). Score ≥ 3 \ge 3 ≥ 3 indicates acute STEMI.

Right Bundle Branch Block (RBBB): QRS duration ≥ 120 \ge 120 ≥ 120 ms; R S R ′ RSR' RS R ′ ("rabbit ears") in leads V1-V2; wide, slurred S wave in lateral leads (I, aVL, V6).

3. Pulmonary Function Testing (PFT) & Spirometry Interpretation

Spirometry and complete pulmonary function testing provide essential physiological data to diagnose, stage, and monitor respiratory diseases. +-----------------------------------------------------------------------------+

  • | STEPWISE PFT INTERPRETATION ALGORITHM |
  • | |
  • | [STEP 1: CHECK FEV1 / FVC RATIO] |
  • | | |
  • | +-----------------------------------+-------------------------------+ |
  • | | | |
  • | v v |
  • | [RATIO <0.70 (or <LLN)] [RATIO >= 0.70 (Normal)]|
  • | OBSTRUCTIVE VENTILATORY DEFECT Check FVC (% predicted)|
  • | | | |
  • | v +---------------+---------------+ |
  • | [STEP 2: ASSESS SEVERITY (FEV1 %)] | | |
  • | - GOLD 1 (Mild): FEV1 >= 80% v v |
  • | - GOLD 2 (Moderate): FEV1 50-79% [FVC >= 80% (Normal)] [FVC < 80% (Reduced)]|
  • | - GOLD 3 (Severe): FEV1 30-49% NORMAL SPIROMETRY SUSPECT RESTRICTIVE PATTERN|
  • | - GOLD 4 (Very Severe): FEV1 < 30% | | |
  • | | v v |
  • | v [CHECK DLCO] [STEP 4: PLETHYSMOGRAPHY]|
  • | [STEP 3: BRONCHODILATOR REVERSIBILITY] - Normal: Healthy Check Total Lung Capacity (TLC)
  • | Administer 4 puffs Albuterol; retest. - Low: Early ILD, - TLC < 80%: CONFIRMED RESTRICTION|
  • | Significant if: Pulmonary HTN, - TLC >= 80%: Air trapping / normal|
  • | - FEV1 or FVC increases by >12% AND >200 mL severe Anemia | |
  • | - Positive = Asthma (or Asthma-COPD overlap) v |
  • | - Negative / Fixed = COPD [STEP 5: EVALUATE DLCO]|
  • | | | |
  • | +-----------------------------------------------------------------------------------+ |
  • | | |
  • | v |
  • | [STEP 5: DIFFUSING CAPACITY (DLCO)] |
  • | | |
  • | +-----------------------------------+-----------------------------------+ |
  • | | | |
  • | v v |
  • | [REDUCED DLCO (<80% predicted)] [NORMAL OR ELEVATED DLCO (>=80%)] |
  • | - Obstructive + Low DLCO = EMPHYSEMA - Obstructive + Normal DLCO = ASTHMA|
  • | - Restrictive + Low DLCO = INTRINSIC PARENCHYMAL ILD or CHRONIC BRONCHITIS |
  • | (Idiopathic Pulmonary Fibrosis, Sarcoidosis, - Restrictive + Normal DLCO = |
  • | Asbestosis, Amiodarone toxicity) EXTRINSIC / CHEST WALL / NEUROMUSCULAR|
  • | - Isolated Low DLCO with normal spirometry = (Obesity hypoventilation, Scoliosis,|
  • | Pulmonary Arterial Hypertension or CTEPH Myasthenia Gravis, ALS, Guillain-Barré)|
  • +-----------------------------------------------------------------------------+
  • Comprehensive Spirometry & DLCO Differentiation Matrix

Diagnostic Classification FEV1/FVC Ratio FVC (% pred) FEV1 (% pred) Bronchodilator Reversibility TLC (% pred) DLCO (% pred) Hallmark Clinical Conditions

Asthma Reduced (<0.70) Normal or Reduced Reduced Positive ( > 12 % >12\% > 12% and > 200 >200 > 200 mL) Normal or Elevated Normal or Elevated ( > 100 % >100\% > 100% ) Bronchial hyperreactivity, atopy, episodic wheezing, triggers.

COPD: Emphysema Reduced (<0.70) Normal or Reduced Reduced Negative (or minimal/fixed) Elevated ( > 120 % >120\% > 120% , hyperinflation) Reduced (<80%) Alveolar-capillary membrane destruction, loss of elastic recoil, tobacco history.

COPD: Chronic Bronchitis Reduced (<0.70) Normal or Reduced Reduced Negative (or minimal/fixed) Normal Normal or Mildly Reduced Chronic productive cough for ≥ 3 \ge 3 ≥ 3 consecutive months in 2 consecutive years.

Intrinsic Restrictive (ILD / IPF) Normal or High ( > 0.75 >0.75 > 0.75 ) Reduced (<80%) Reduced Negative Reduced (<80%) Markedly Reduced (<60%) Idiopathic pulmonary fibrosis, sarcoidosis, hypersensitivity pneumonitis, drug toxicity (amiodarone, bleomycin, nitrofurantoin).

Extrinsic Restrictive (Chest Wall / Neuromuscular) Normal or High ( > 0.75 >0.75 > 0.75 ) Reduced (<80%) Reduced Negative Reduced (<80%) NORMAL ( ≥ 80 % \ge 80\% ≥ 80% ) Severe kyphoscoliosis, morbid obesity hypoventilation syndrome, ALS, myasthenia gravis, diaphragmatic paralysis.

Pulmonary Vascular Disease Normal ( ≥ 0.70 \ge 0.70 ≥ 0.70 ) Normal ( ≥ 80 % \ge 80\% ≥ 80% ) Normal ( ≥ 80 % \ge 80\% ≥ 80% ) Negative Normal ( ≥ 80 % \ge 80\% ≥ 80% ) Isolated Reduction (<80%) Pulmonary Arterial Hypertension (PAH), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), severe anemia.